查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球糖尿病神經病變市場 - 2023-2030年
市場調查報告書
商品編碼
1285064

全球糖尿病神經病變市場 - 2023-2030年

Global Diabetic Neuropathy Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概況

全球糖尿病神經病變市場在2022年達到37.754億美元，預計到2030年將見證有利可圖的成長，達到62.981億美元。在預測期間（2023-2030年），糖尿病神經病變市場預計將呈現6.7%的複合年成長率。

糖尿病神經病變是由於糖尿病引起的神經惡化，通常會促使腳或小腿的疼痛和感覺喪失。根據神經病變的影響，在不同的身體部位如臀部、手腕和背部都會遇到疼痛。有不同類型的神經病變，如局灶性神經病變、近端神經病變、周圍神經病變和自主神經病變。

糖尿病患者和老年人口數量的成長，以及各政府組織不斷增加的資助計劃，都在推動全球糖尿病神經病變市場的成長。

市場動態

不斷成長的老年人口預計將在預測期內推動全球糖尿病神經病變市場。

神經病在65歲以上的人中非常典型，而且隨著年齡的成長，神經病的比例也在上升。因此，老年人口的成長正在推動全球糖尿病神經病變市場。例如，根據聯合國發布的《2022年世界人口前景》，80歲或以上的人的數量預計將成長三倍，從2022年的1.57億增加到2050年的4.59億。

各種政府組織不斷增加的資金為全球糖尿病神經病變市場提供了潛在的成長機會

各個政府組織不斷增加的資金計劃正在為全球糖尿病神經病變市場提供有利可圖的成長機會。例如，美國衛生與公眾服務部通過印第安人健康服務，為2023財政年度的印第安人特別糖尿病計劃（SDPI）提供1.39億美元的資金，為美國阿拉斯加和印第安原住民社區提供糖尿病預防和治療援助。

COVID-19影響分析

COVID-19分析包括COVID前情景、COVID情景和COVID後情景以及定價動態（包括大流行期間和之後的定價變化與COVID前情景的比較）、需求-供應譜（由於貿易限制、封鎖和後續問題造成的需求和供應變化）、政府計劃（政府機構振興市場、部門或行業的計劃）和製造商戰略計劃（這裡將涉及製造商為緩解COVID問題所做的努力）。

俄烏戰爭影響分析

在烏克蘭，慢性病患者目前遇到的問題是由於缺乏醫療支持，如慢性病的藥物，而此時，由於入侵，電力、供暖和清潔水等基本需求沒有得到關注。因此，俄烏戰爭對全球糖尿病神經病變市場產生了負面影響。

全球經濟衰退影響分析

醫療保健行業並非完全不受經濟衰退的影響，因為在過去的金融衰退中，醫療保健機構應該進行裁員和招聘。這說明該企業與不同行業相比，確實管理得更好。然而，隨著通貨膨脹的到來，經濟衰退的威脅給市場帶來了風險。

由於全球已開發國家的高通脹率，有關持續衰退的壓力程度擴大，在過去兩年中出現了全方位的價格波紋。

人工智慧影響分析

人工智慧預計將對全球糖尿病神經病變市場產生積極影響，因為隨著人工智慧處理巨量資料池的能力，結合病人的經驗可以直接帶來預測性的好處，使醫療保健生態系統能夠暴露出需要修改的病人護理的關鍵層面。

目錄

第一章：方法和範圍

  • 研究方法
  • 報告的研究目標和範圍

第二章：定義和概述

第三章：執行摘要

  • 按類型分析
  • 按藥物類型分類
  • 按配銷通路分類
  • 按地區分類

第四章：動態變化

  • 影響因素
    • 驅動因素
      • 越來越多的糖尿病病例
      • 市場的發展
    • 限制因素
      • 嚴格的監管機構
    • 機會
    • 政府計劃
    • 影響分析

第五章：行業分析

  • 波特的五力分析
  • 監管分析
  • 價格分析
  • 專利分析

第六章：COVID-19分析

  • COVID-19的分析
    • COVID-19之前的情況
    • COVID-19期間的情況
    • 後COVID-19及未來的情況
  • 在COVID-19期間的定價動態
  • 需求-供應譜系
  • 大流行期間與市場有關的政府計劃
  • 製造商的戰略計劃
  • 結語

第7章：俄羅斯-烏克蘭戰爭分析

第八章：全球經濟衰退分析

第九章：人工智慧分析

第十章：按類型

  • 周邊神經病變
  • 自主神經病變
  • 近端神經病變
  • 局部神經病變

第十一章：按藥物類別分類

  • 抗抑鬱藥
  • 抗驚厥劑
  • 鴉片類藥物
  • 非類固醇類藥物
  • 其他

第12章：按配銷通路分類

  • 醫院和診所藥房
  • 零售藥店和商店和商店
  • 網上藥店

第十三章：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美其他地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 亞太其他地區
  • 中東和非洲

第十四章：競爭格局

  • 競爭格局
  • 市場佔有率分析
  • 合併和收購分析

第十五章：公司簡介

  • Depomed Pharma
    • 公司概述
    • 類型組合和描述
    • 財務概況
    • 主要發展情況
  • Eli Lilly and Company
  • Daiichi Sankyo
  • Teva Pharmaceutical Industries Ltd.
  • Xenoport
  • Grunenthal
  • Johnson and Johnson
  • Pfizer
  • GlaxoSmithKline
  • Boehringer Ingelheim

第16章：附錄

簡介目錄
Product Code: PH258

Market Overview

The global diabetic neuropathy market reached USD 3,775.4 million in 2022 and is projected to witness lucrative growth by reaching up to USD 6,298.1 million by 2030. The diabetic neuropathy market is expected to exhibit a CAGR of 6.7% during the forecast period (2023-2030).

Diabetic neuropathy is the deterioration induced to the nerve because of diabetes, which usually causes pain and loss of sensation in the feet or lower legs. The pain can be encountered in different body parts like hips, wrists, and back based on the impact of neuropathy. There are different types of neuropathy like focal neuropathy, proximal neuropathy, peripheral neuropathy, and autonomic neuropathy.

The growing number of diabetes patients and the geriatric population, and increasing funding initiatives from various government organizations are driving the global diabetic neuropathy market growth.

Market Dynamics

The Growing Geriatric Population is Expected to Drive The Global Diabetic Neuropathy Market Over The Forecast Period.

Neuropathies are exceptionally typical in individuals over 65 years old and their preponderance upsurges with age. Thus, the growing geriatric population is driving the global diabetic neuropathy market. For instance, according to the World Population Prospects 2022, from the UN, the number of individuals aged 80 or above is anticipated to grow triple fold, from 157 million in 2022 to 459 million by 2050.

The Increasing Funding from Various Government Organizations is Providing the Global Diabetic Neuropathy Market with Prospective Growth Opportunities

The increasing funding initiatives from various government organizations are presenting the global diabetic neuropathy market with lucrative growth opportunities. For instance, the U. S. Department of Health and Human Services, via the Indian Health Service, is funding $139 million for the Fiscal Year 2023 Special Diabetes Program for Indians (SDPI) to deliver diabetes prevention and therapy assistance for American Alaska and Indian Native communities.

COVID-19 Impact Analysis

The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario along with pricing dynamics (including pricing change during and post-pandemic comparing it to pre-COVID scenarios), demand-supply spectrum (shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), government initiatives (initiatives to revive market, sector or industry by government bodies) and manufacturers strategic initiatives (what manufacturers did to mitigate the COVID issues will be covered here).

Russia-Ukraine War Impact Analysis

The issues that are currently being encountered by individuals with chronic conditions in Ukraine are increased by a deficiency of medical support such as medications for chronic disorders at a time when fundamental requirements like electricity, heating, and clean water are not being attended, to because of the invasion. Thus, the Russia-Ukraine war has negatively impacted the global diabetic neuropathy market.

Global Recession Impact Analysis

The healthcare industry is not completely invulnerable to a recession, as healthcare organizations supposed layoffs and hirings in past financial downturns. That remarked the enterprise does manage better compared to different sectors. Yet, the threat of recession risks the market as inflation succeeds.

The extended degree of stress concerning the ongoing recession as the high inflation in developed countries worldwide has transpired in an all-around price ripple through the past two years.

Artificial Intelligence Impact Analysis

AI is anticipated to hold a positive influence on the global diabetic neuropathy market as with AI's capacity to process big data pools, combining patient experiences can direct to predictive benefits, enabling the healthcare ecosystem to expose key dimensions of patient care that need revision.

Segment Analysis

The global diabetic neuropathy market is segmented based on type, drug class, distribution channel, and region.

The NSAIDS Segment is Estimated To Hold a 35.4% Share of the Global Market

The NSAIDs segment is estimated to hold the largest share of the global diabetic neuropathy market, owing to the easy availability of the NSAIDs as are over the counter and hence, readily available for patients in their residents. Additionally, majority of the NSAIDs have their generic formulations obtainable in the market making them affordable and these drugs deliver quick relief without any severe side effects.

Geographical Analysis

Europe is Estimated to Hold the Second-Largest Share of the Global Diabetic Neuropathy Market During the Forecast Period

Owing to the increasing incidence of diabetes, Europe is estimated to hold about 26.3% of the global diabetic neuropathy market. For instance, according to WHO, there are over 60 million individuals with diabetes in the European region, or nearly 10.3% of males and 9.6% of females aged 25 years and above. The preponderance of diabetes is rising among all generations in the European region, primarily because of the increase in overweight and obesity, unhealthy food consumption, and less physical inactivity.

Competitive Landscape

The major global players in the market include: Depomed Pharma, Eli Lilly, Daiichi Sankyo, Teva Pharmaceutical Industries Ltd., Xenoport, Grunenthal, Johnson and Johnson, Pfizer, GlaxoSmithKline, and Boehringer Ingelheim among others.

WHY PURCHASE THE REPORT?

  • To visualize the global diabetic neuropathy market segmentation based on type, drug class, distribution channel, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of diabetic neuropathy market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global diabetic neuropathy market report would provide approximately 53 tables, 54 figures, and 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Drug Type
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Cases of Diabetes
      • 4.1.1.2. Market Developments
    • 4.1.2. Restraints
      • 4.1.2.1. Stringent Regulatory Authorities
    • 4.1.3. Opportunity
    • 4.1.4. Government Initiatives
    • 4.1.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Regulatory Analysis
  • 5.3. Pricing Analysis
  • 5.4. Patent Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Post COVID-19 & Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Global Recession Analysis

9. Artificial Intelligence Analysis

10. By Type

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.1.2. Market Attractiveness Index, By Type
  • 10.2. Peripheral Neuropathy
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Autonomic Neuropathy
  • 10.4. Proximal Neuropathy
  • 10.5. Focal Neuropathy

11. By Drug Class

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.1.2. Market Attractiveness Index, By Drug Class
  • 11.2. Anti-Depressant
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Anti-Convulsant
  • 11.4. Opioids
  • 11.5. NSAIDs
  • 11.6. Others

12. By Distribution Channel

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.1.2. Market Attractiveness Index, By Distribution Channel
  • 12.2. Hospitals and Clinics Pharmacy
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Retail Pharmacy and Stores and Stores
  • 12.4. Online Pharmacy

13. By Region

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 13.1.2. Market Attractiveness Index, By Region
  • 13.2. North America
    • 13.2.1. Introduction
    • 13.2.2. Key Region-Specific Dynamics
    • 13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.2.6.1. The U.S.
      • 13.2.6.2. Canada
      • 13.2.6.3. Mexico
  • 13.3. Europe
    • 13.3.1. Introduction
    • 13.3.2. Key Region-Specific Dynamics
    • 13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.3.6.1. Germany
      • 13.3.6.2. The U.K.
      • 13.3.6.3. France
      • 13.3.6.4. Italy
      • 13.3.6.5. Spain
      • 13.3.6.6. Rest of Europe
  • 13.4. South America
    • 13.4.1. Introduction
    • 13.4.2. Key Region-Specific Dynamics
    • 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.4.6.1. Brazil
      • 13.4.6.2. Argentina
      • 13.4.6.3. Rest of South America
  • 13.5. Asia-Pacific
    • 13.5.1. Introduction
    • 13.5.2. Key Region-Specific Dynamics
    • 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.5.6.1. China
      • 13.5.6.2. India
      • 13.5.6.3. Japan
      • 13.5.6.4. Australia
      • 13.5.6.5. Rest of Asia-Pacific
  • 13.6. Middle East and Africa
    • 13.6.1. Introduction
    • 13.6.2. Key Region-Specific Dynamics
    • 13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

14. Competitive Landscape

  • 14.1. Competitive Scenario
  • 14.2. Market Share Analysis
  • 14.3. Mergers and Acquisitions Analysis

15. Company Profiles

  • 15.1. Depomed Pharma
    • 15.1.1. Company Overview
    • 15.1.2. Type Portfolio and Description
    • 15.1.3. Financial Overview
    • 15.1.4. Key Developments
  • 15.2. Eli Lilly and Company
  • 15.3. Daiichi Sankyo
  • 15.4. Teva Pharmaceutical Industries Ltd.
  • 15.5. Xenoport
  • 15.6. Grunenthal
  • 15.7. Johnson and Johnson
  • 15.8. Pfizer
  • 15.9. GlaxoSmithKline
  • 15.10. Boehringer Ingelheim

LIST NOT EXHAUSTIVE

16. Appendix

  • 16.1. About Us and Services
  • 16.2. Contact Us